Andere talen NANO MRNA Co.,Ltd.

Aandelen

4571

JP3651120002

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 21-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
172 ^JPY	0,00%		-0,58%	-9,47%

2023	NANO MRNA Co., Ltd. en Kao Corporation sluiten een uitgebreide samenwerkingsovereenkomst voor onderzoek naar mRNA-geneesmiddelen	CI
2023	NanoCarrier Co. Rapporteert winstresultaten voor het volledige jaar eindigend op 31 maart 2023	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases	15/11
NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery	14/11
NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	12-06-23
NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	26-05-23
NanoCarrier Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	12-05-23
US Patent Office Grants Patrys Two New Deoxymab Patents	18-04-23
NanoCarrier Co., Ltd. announced that it has received Â¥1.11096909 billion in funding from Whiz Partners Inc.	13-02-23
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.11096909 billion in funding from Whiz Partners Inc.	25-01-23
NanoCarrier Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022	11-11-22
InnoCan Pharma Corporation: Innocan Pharma berichtet über weitere Erfolge bei der Profilcharakterisierung von Mikro-RNA in seinem Projekt für eine Verabreichungsplattform für mit Cannabinoiden beladenen Exosomen (CLX)	10-11-21
NanoCarrier : Commences in Domestic Patients Administration of VB-111, a gene therapy product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	10-06-21
NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	10-06-21
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.15292206 billion in funding from THE KENKO FUTURE Limited Partnership	23-04-21
Nanocarrier : Concludes NC-6004 Phase III Clinical Study for Pancreatic Cancer	30-11-20
NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer	27-11-20
Nanocarrier : Administers Head and Neck Cancer Drug NC-6004 to First Patient	06-11-20
Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer	05-11-20
NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda	26-10-20
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.	30-09-20
NanoCarrier Co., Ltd. Announces the First Participant Dosed in Investigator-Initiated Phase I Clinical Trial in Patients with Breast Cancer in Japan	03-09-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NANO MRNA Co.,Ltd.

Aandelen

4571

JP3651120002

Andere talen

Filters